visugromab
1 product
2 abstracts
Abstract
Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer.Org: University of Navarra Clinic, Pamplona, Spain, START-CIOCC Hospital Universitario HM Sanchinarro, Madrid, Spain, Medical Oncology Department, Catalan Institute of Oncology (ICO), L'hospitalet De Llobregat, Spain, Department of Oncology/Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland, Department of Hematology/Oncology, University of Wuerzburg, Wuerzburg, Germany,
Abstract
Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL).Org: START Madrid-CIOCC/University Hospital Sanchinarro, Early Drug Development Group, Division of Medical Oncology, National Cancer Center Singapore, Medical Oncology Department, CatalYm,
Product
visugromab + nivolumab